Introduction {#j_jomb-2018-0018_s_001}
============

Cardiac surgery carries a greater risk for perioperative acute kidney injury (AKI) than any other type of surgery ([@j_jomb-2018-0018_ref_001]). Cardiac surgery-associated AKI (CSA-AKI) occurs in approximately 22% of cardiac surgery patients and is linked to a 5-fold increase in mortality ([@j_jomb-2018-0018_ref_002], [@j_jomb-2018-0018_ref_003], [@j_jomb-2018-0018_ref_004]). Given the limited prevention and treatment strategies, recognition of patients at risk for development of CSA-AKI is of paramount importance. Risk assessment has, so far, been restricted to risk scores, and, arguably, novel biomarkers of AKI.

The best validated risk scores ([@j_jomb-2018-0018_ref_005], [@j_jomb-2018-0018_ref_006], [@j_jomb-2018-0018_ref_007]) are focused on predicting severe CSA-AKI requiring dialysis although mild CSA-AKI is far more likely to occur ([@j_jomb-2018-0018_ref_003]). The only scoring system designed to predict all stage CSA-AKI is Leicester Cardiac Surgery Research AKI Risk Score ([@j_jomb-2018-0018_ref_008]) but it still needs an external validation. It is very important to acknowledge that CSA-AKI could also occur in patients that are assessed as lowrisk by available scores.

Novel biomarkers such as Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule-1 (KIM-1) have been studied as potential biomarkers of CSA-AKI with conflicting results ([@j_jomb-2018-0018_ref_009], [@j_jomb-2018-0018_ref_010]). High costs, absence of clear recommendations as well as difficult interpretation are preventing their routine use.

Lactate is routinely measured biomarker of tissue hypoperfusion. Hyperlactatemia is common in cardiac surgery especially if cardiopulmonary bypass (CPB) is employed ([@j_jomb-2018-0018_ref_011]). Its association with increased morbidity and mortality is well known ([@j_jomb-2018-0018_ref_012], [@j_jomb-2018-0018_ref_013], [@j_jomb-2018-0018_ref_014], [@j_jomb-2018-0018_ref_015]) but only few recent studies suggested that it might be linked to development of CSA-AKI ([@j_jomb-2018-0018_ref_013], [@j_jomb-2018-0018_ref_014], [@j_jomb-2018-0018_ref_016], [@j_jomb-2018-0018_ref_017]).

We aimed to evaluate urinary NGAL (uNGAL), KIM-1 and lactate concentrations as biomarkers of CSA-AKI in patients undergoing elective cardiac surgery that are assessed as low-risk for development of CSA-AKI.

Materials and Methods {#j_jomb-2018-0018_s_002}
=====================

This prospective observational study was conducted at the tertiary level adult cardiac surgery university hospital. The study was approved by the institutional Ethical Committee and performed in conformance with the Declaration of Helsinki ethical guidelines. All patients included in this study signed an informed consent form.

Patients {#j_jomb-2018-0018_s_002_s_001}
--------

A total of 100 adult consecutive consenting patients fulfilling study criteria were recruited. Inclusion criteria were age ≥ 18 years, elective cardiac surgery with cardiopulmonary CPB including coronary artery bypass grafting (CABG), valve surgery or combined CABG and valve surgery, normal preoperative kidney function and low risk for developing CSA-AKI. Exclusion criteria were age \< 18 years, emergency or redo surgery, preoperative AKI or chronic kidney disease and medium or high risk for developing of CSA-AKI. Kidney function was considered normal if eGFR estimated by Modification of Diet in Renal Disease (MDRD) study equation ([@j_jomb-2018-0018_ref_018]) was \> 60 ml/min per 1.73m^2^ ([@j_jomb-2018-0018_ref_019]). Risk for developing of CSA-AKI was assessed according to Cleveland Clinic Score ([@j_jomb-2018-0018_ref_005]). Patients with Cleveland Clinic Score ≤ 5 are considered to be at low risk for developing CSA-AKI. CSA-AKI was diagnosed according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria ([@j_jomb-2018-0018_ref_020]). Rapid reversal CSA-AKI was defined by an episode of AKI that lasts ≤ 48 h or less and acute kidney disease (AKD) by duration of AKI ≥ 7 days (21). All patients received routine perioperative care.

Age, gender, type of surgery, duration of CPB, duration of aortic cross-clamping, intraoperative blood loss and intraoperative blood transfusion were recorded. Body mass index (BMI) was calculated based on anthropometric evaluation (weight, height). Leicester Cardiac Surgery Research AKI Risk Score in which percent value presents probability for CSA-AKI development was also calculated ([@j_jomb-2018-0018_ref_008]).

Samples {#j_jomb-2018-0018_s_002_s_002}
-------

Arterial blood and urine samples were collected simultaneously at predetermined time-points: preoperatively (before the induction of anaesthesia), immediately after the end of CPB and 3, 12, 24 and 48 hours after the end of CPB. Lactate levels were measured immediately after collection using blood gas analyzer Gem Premier 3000, Instrumentation Laboratory, Milano, Italy. Serum creatinine levels were measured on the day of collection employing routine laboratory method (AU680, Beckman Coulter, USA). Urine samples were centrifuged and stored at -80C until further analysis. Urine NGAL and KIM-1 levels were measured using Enzyme-linked Immunosorbent Assay (ELISA) method (ABBOTT Diagnostics, IL, USA and R&D Systems Inc, MN, USA, respectively).

Statistical analysis {#j_jomb-2018-0018_s_002_s_003}
--------------------

Statistical analysis was performed in SPSS Statistics Version 25 software (SPSS Inc., Chicago, IL, USA). The normality of data was assessed with Kolmogorov-Smirnov test. The data are presented as median and 25^th^ to 75^th^ quartile or frequencies. The differences between the groups were compared using the Mann-Whitney U or Chi square test, where appropriate. The within-group variations were analyzed using the Friedman's test. A univariate binary logistic regression analysis was employed to test possible predictors of CSA-AKI. The significance level for all statistical tests was set at 0.05.

Results {#j_jomb-2018-0018_s_003}
=======

In our study, 15 out of 100 low-risk cardiac surgery patients developed CSA-AKI. Twelve of CSA-AKI patients had rapid reversal AKI (stage 1 according to KDIGO definition) and 3 had AKD (stage 2 according to KDIGO definition).

Baseline characteristics of the patient groups are shown in *[Table I](#j_jomb-2018-0018_tab_001){ref-type="table"}*. Statistically significant difference between patients with and without CSA-AKI in age, gender, BMI, type of surgery, intraoperative blood loss and transfusion was not found. As expected from the study design, patients with and without CSA-AKI had similar Cleveland Clinic Scores but patients with CSA-AKI had significantly higher risk for developing CSA-AKI according to Leicester Cardiac Surgery Research AKI Risk Score. Although only patients with normal kidney function were included, patients that developed CSA-AKI had significantly higher creatinine levels but similar uNGAL and KIM-1 levels compared to patients without CSA-AKI. CSA-AKI patients also had longer hospitalization, CPB and aortic cross-clamping duration.

###### 

Comparison of the baseline characteristics of the patients with and without CSA-AKI.

                                                          Overall (n = 100)          Without CSA-AKI (n = 85)   With CSA-AKI (n = 15)      P
  ------------------------------------------------------- -------------------------- -------------------------- -------------------------- -------
  Age (years)                                             63.0 \[56.25 -- 69.0\]     63.0 \[57.0 -- 68.5\]      68.0 \[60.0 -- 73.0\]      0.087
  Gender (male/female)                                    77 / 23                    66 / 19                    11 / 4                     0.714
  BMI (kg/m^2^)                                           27.5 \[25.4 -- 29.4\]      27.3 \[25.4 -- 29.4\]      28.1 \[26.0 -- 29.3\]      0.612
  Surgery (valve/CABG/valve + CABG)                       21 / 75 / 4                18/65/2                    3/10/2                     0.134
  Duration of CPB (min)                                   80.0 \[64.0 -- 97.7\]      75.0 \[59.5 -- 93.0\]      101.0 \[74.0 -- 110.0\]    0.012
  Duration of aortic cross-clamping (min)                 44.5 \[30.0 -- 60.0\]      40 \[29.5 -- 52.0\]        55.0 \[39.0 -- 71.0\]      0.024
  Intraoperative blood loss (mL)                          1200 \[1000 -- 1575\]      1200 \[1000 -- 1500\]      1400 \[1200 -- 2000\]      0.052
  Intraoperative transfusion (mL)                         470 \[415 -- 590\]         450 \[405 -- 565\]         576 \[430 -- 714\]         0.082
  Hospitalisation (days)                                  6 \[5 -- 7\]               6 \[6 -- 7\]               7 \[6 -- 12\]              0.017
  Cleveland Clinic Score (0 /1 / 2)                       39 / 22 / 19               35 /17 /17                 4 / 4 / 3                  0.514
  Leicester Cardiac Surgery Research AKI Risk Score (%)   11.51 \[8.44 -- 15.96\]    11.41 \[7.41 -- 15.23\]    15.17 \[11.24 -- 19.10\]   0.018
  Baseline creatinine (µmol/L)                            74.0 \[65.0 -- 83.0\]      71.0 \[64.5 -- 80.5\]      89.0 \[70.0 -- 96.0\]      0.025
  Baseline eGFR (mL/min/1.73 m^2^)                        93.3 \[81.3 -- 109.8\]     95.6 \[85.1 -- 110.2\]     76.4 \[64.5 -- 90.5\]      0.002
  Lactate (mmol/L)                                        1.30 \[1.00 -- 1.70\]      1.3 \[1.0 -- 1.6\]         1.2 \[0.9 -- 1.8\]         0.656
  uNGAL (ng/mL)                                           3.12 \[0.39 -- 11.78\]     3.52 \[0.51 -- 12.36\]     2.36 \[0.25 -- 6.02\]      0.457
  KIM-1 (pg/mL)                                           382.0 \[123.5 -- 936.0\]   437.5 \[136.0 -- 946.2\]   256.5 \[86.0 -- 760.5\]    0.231

Data are presented as median and interquartile range or frequencies. Mann-Whitney U test, Chi-squire test. CSA-AKI -- Cardiac surgery-associated cute kidney injury; BMI -- Body mass index; eGFR -- Estimated glomerular filtration rate; uNGAL -- Urinary Neutrophil Gelatinase-Associated Lipocalin; KIM-1 -- Kidney Injury Molecule-1; CABG -- Coronary artery bypass graft; CPB -- Cardiopulmonary bypass.

*[Figure 1](#j_jomb-2018-0018_fig_001){ref-type="fig"}* depicts serial measurements of lactate (A), urinary NGAL (B) and KIM-1 (C) in patients with and without CSA-AKI. After the end of CPB, a significant increase in concentrations of all three biomarkers was noted (p \< 0.05 for all timepoints, except for lactate at 48 h and uNGAL after completion of CPB). Compared to patients without CSA-AKI, patients with CSA-AKI had significantly higher lactate levels at all time point except at the CPB end. A significant difference in uNGAL and KIM-1 levels between patients with and without CSA-AKI was not found except for uNGAL 3 h after CPB.

![Serial (A) lactate, (B) uNGAL and (C) KIM-1 measurements in patients with and without CSA-AKI.\
Data are presented as median and 95% C.I. ^∗^Statistically significant difference (p \< 0.05) between patients with and without CSA-AKI at specified time point, Mann-Whitney U test. CSA-AKI -- Cardiac surgery-associated acute kidney injury; uNGAL -- Urinary Neutrophil Gelatinase-Associated Lipocalin; KIM-1 -- Kidney Injury Molecule-1; CPB -- Cardiopulmonary bypass.](jomb-38-118-g001){#j_jomb-2018-0018_fig_001}

A univariate binary logistic regression was performed in order to identify independent predictors of CSA-AKI (*[Table II](#j_jomb-2018-0018_tab_002){ref-type="table"}*). As expected, absolute lactate levels at 3, 12, 24 and 48 h after the end of CPB were independent predictors of CSA-AKI with highest odds ratio of 2.72 for lactate levels at 24 h after the end of CPB. Interestingly, the differences in lactate concentrations between various time points as well as peak lactate concentration had lower prediction value then the absolute lactate concentration. However, peak lactate ≥ 4 mmol/L was associated with 6.33 times higher probability for developing CSA-AKI. Baseline creatinine and eGFR as well as duration of CPB and aortic cross-clamping were also independent predictors of CSA-AKI.

###### 

A univariate binary logistic regression for prediction of CSA-AKI.

                                                      Odds Ratio \[95% C.I.\]      p
  --------------------------------------------------- ---------------------------- -------
  Creatinine (baseline)                               1.056 \[0.1.013 -- 0.101\]   0.009
  eGFR (baseline)                                     0.947 \[0.910 -- 0.984\]     0.006
  Cleveland Clinic Score                              1.164 \[0.600 -- 2.258\]     0.653
  Leicester Cardiac Surgery Research AKI Risk Score   1.047 \[0.986 -- 1.113\]     0.135
  Duration of CPB                                     1.016 \[1.000 -- 1.032\]     0.048
  Duration of aortic cross-clamping                   1.022 \[1.002 -- 1.043\]     0.030
                                                                                   
  Lactate (baseline)                                  0.664 \[0.204 -- 2.159\]     0.496
  Lactate (CPB)                                       1.540 \[0.831 -- 2.852\]     0.170
  Lactate (3 h)                                       1.410 \[1.022 -- 1.944\]     0.036
  Lactate (12 h)                                      1.470 \[1.007 -- 2.146\]     0.046
  Lactate (24 h)                                      2.721 \[1.485 -- 4.986\]     0.001
  Lactate (48 h)                                      2.436 \[1.227 -- 4.837\]     0.011
                                                                                   
  Lactate (CPB -- baseline)                           1.936 \[0.981 -- 3.821\]     0.057
  Lactate (3h -- baseline)                            1.443 \[1.034 -- 2.015\]     0.031
  Lactate (12 h -- baseline)                          1.501 \[1.026 -- 2.195\]     0.036
  Lactate (24 h -- baseline)                          2.569 \[1.460 -- 4.546\]     0.001
  Lactate (48 h -- baseline)                          2.031 \[1.109 -- 3.719\]     0.022
                                                                                   
  Lactate (3h -- CPB)                                 1.503 \[1.013 -- 2.230\]     0.043
  Lactate (12 h -- CPB)                               1.457 \[0.930 -- 2.283\]     0.100
  Lactate (24 h -- CPB)                               2.173 \[1.224 -- 3.585\]     0.008
  Lactate (48 h -- CPB)                               1.369 \[0.773 -- 2.422\]     0.281
                                                                                   
  Lactate (12 h -- 3h)                                0.891 \[0.604 -- 1.313\]     0.559
  Lactate (24 h -- 3h)                                1.003 \[0.683 -- 1.475\]     0.986
  Lactate (48 h -- 3h)                                0.861 \[0.627 -- 1.181\]     0.352
                                                                                   
  Lactate (24 h -- 12h)                               1.310 \[0.725 -- 2.368\]     0.371
  Lactate (48 h -- 12 h)                              0.890 \[0.598 -- 1.325\]     0.566
                                                                                   
  Lactate (48 h -- 24 h)                              0.596 \[0.331 -- 1.074\]     0.085
                                                                                   
  Peak lactate                                        1.067 \[0.939 -- 1.212\]     0.009
  Peak lactate ≥ 4 mmol/L                             6.330 \[1.957 -- 20.472\]    0.001

Data are presented as odds ratio and 95% C.I. Univariate binary logistic regression. CSA-AKI -- Cardiac surgery-associated acute kidney injury; eGFR -- Estimated glomerular filtration rate; CPB -- Cardiopulmonary bypass.

Discussion {#j_jomb-2018-0018_s_004}
==========

Most of the research on prediction of CSA-AKI is focused on identifying high-risk patients. However, CSA-AKI also occurs in patients that are classified as low-risk so it is reasonable to assume that certain risk factors are missed by available risk scores. To identify low-risk patients we used Cleveland Clinic Score. Cleveland Clinic Score is best validated but, effectively, predicts only severe CSA-AKI that requires dialysis ([@j_jomb-2018-0018_ref_005]). On the other hand, Leicester Cardiac Surgery Research Acute Kidney Injury Risk Score predicts any stage CSA-AKI but has debatable application outside UK healthcare system ([@j_jomb-2018-0018_ref_008]). It is therefore not surprising that our patients with CSA-AKI had similar both Cleveland Clinic scores to patients without CSA-AKI (*[Table I](#j_jomb-2018-0018_tab_001){ref-type="table"}*).

As expected, a significant increase of uNGAL and KIM-1 levels after CPB was observed (*[Figure 1B](#j_jomb-2018-0018_fig_001){ref-type="fig"}* and *[1C](#j_jomb-2018-0018_fig_001){ref-type="fig"}*). An increase in uNGAL levels after CPB was already demonstrated in patients without CSA-AKI ([@j_jomb-2018-0018_ref_022], [@j_jomb-2018-0018_ref_023]) and could be a consequence of systemic inflammation caused by CPB. A significant difference in either uNGAL or KIM-1 levels between patients with and without CSA-AKI was not found which implies that both biomarkers have poor diagnostic and predictive value as previously reported ([@j_jomb-2018-0018_ref_009], [@j_jomb-2018-0018_ref_010], [@j_jomb-2018-0018_ref_024], [@j_jomb-2018-0018_ref_025], [@j_jomb-2018-0018_ref_026], [@j_jomb-2018-0018_ref_027]). Bulluck at al. ([@j_jomb-2018-0018_ref_028]) demonstarted that preexisting chronic kidney disease (CKD) could also alter NGAL and KIM-1 levels and, consequently, affect their levels during and after surgery. Patients with pre-existing CKD were excluded from our study.

In our study lactate concentrations significantly increased after the end of CPB and were significantly higher in patients with CSA-AKI (*[Figure 1A](#j_jomb-2018-0018_fig_001){ref-type="fig"}*). Consequently, postoperative lactate was good predictor of CSA-AKI with the highest OR 2.7 for levels at 24 h after the end of CPB, close to previously reported ([@j_jomb-2018-0018_ref_013]). To our surprise, the differences in lactate concentrations between various time points had lower prediction value then the absolute lactate concentration (*[Table II](#j_jomb-2018-0018_tab_002){ref-type="table"}*). Mak et al. ([@j_jomb-2018-0018_ref_013]) found that persistent hyperlactatemia is more important determinant of postoperative outcome than the absolute lactate concentration but their study included patients at high risk for developing CSA-AKI and only those with lactate ≥ 3 mmol/L. According to our results (*[Table II](#j_jomb-2018-0018_tab_002){ref-type="table"}*), low-risk patients with peak lactate concentration ≥ 4 mmol/L were 6.3 times more likely to develop CSA-AKI similarly to findings of Naik et al. ([@j_jomb-2018-0018_ref_014]) although their study population included high-risk patients. Normalized lactate load ([@j_jomb-2018-0018_ref_016]), although more comprehensive, is labour intensive and, therefore, not very likely used by clinicians.

This study has numerous limitations including small number of patients, short observational period, infrequent sampling etc. Our results need to be confirmed by other researches with larger patient cohorts, patients with high risk for developing CSA-AKI and also pediatric cardiac surgery patients.

Conclusions {#j_jomb-2018-0018_s_005}
===========

Our results suggest that, as opposed to uNGAL and KIM-a, absolute lactate levels could serve as reliable biomarkers of CSA-AKI even in cardiac surgery patients with low risk for developing CSA-AKI. Given the dramatic increase in CSA-AKI risk, a high level of vigilance for lactate concentrations ≥ 4 mmol/L should be maintained. Further investigations are needed to backup these conclusions.
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